beta
IA Trial Radar

Mostrando ensayos clínicos realizados em: Estados Unidos.

Puedo ayudarle a entender sus condiciones de salud, tratamientos o encontrar ensayos clínicos cercanos.
Nuestra herramienta de búsqueda solo admite inglés. Para búsquedas y discusiones en otros idiomas, use la IA Trial Radar o seleccione los filtros de condición médica y ubicación a continuación.
236 resultados
Mostrando los 50 primeros
 
Estado (Por defecto)
Aún No Recluta, Reclutando, Activo, No Reclutando
×
 
Ubicaciones
Estados Unidos
×
 
Intervención
GLP-1
×
 
Título del estudio
Estado
Dietary Insights and Nutrition Experiences in Adults on GLP-1 Therapy - A Study on Diet Quality Changes in Adults on GLP-1 Therapy (DINE-GLP1) NCT07313384
Reclutando
Efficacy of GLP-1 Receptor Agonists in Treating Upper and Lower Extremity Lymphedema NCT07012642
Reclutando
Impact GLP-1 Agonists Following Bariatric NCT06132477
Reclutando
GLP-1 RA on Liver OMICS in MASLD NCT06982378
Aún no recluta
Impact of Glucagon-like Peptide-1 (GLP-1) Analogs on Disease Outcomes in Psoriatic Arthritis: A Pragmatic Randomized Controlled Trial NCT07111494
Aún no recluta
GLP-1 and Hypoglycemia NCT01858896
Activo, no reclutando
People With Multiple Sclerosis Treated With Ocrelizumab and GLP-1 Agonists NCT07207148
Reclutando
Identifying Changes in Food Behaviors Associated With Beginning GLP-1 Medication NCT06843512
Reclutando
Pelvic Floor Disorder Symptoms in Women Seeking Weight Loss Therapy NCT07175805
Aún no recluta
Combination Therapy for Alcohol Use Disorder NCT07249554
Aún no recluta
Evaluar el impacto del ácido poli-l-láctico en sujetos con glp1 NCT07217743
Aún no recluta
Prolongation of GLP-1 Adherence When Using Continuous Glucose Monitoring NCT06668935
Reclutando
Beta Cell Function in Type 2 Diabetes: Differential Effects of SGLT2 Inhibitors and GLIP-Receptor Agonists NCT07325435
Activo, no reclutando
Bone Metabolism in 12-21 Year Olds Undergoing GLP-1 Receptor Agonist Therapy NCT06903923
Reclutando
Increased Dietary Protein Intake During GLP-1 Medication Use (in Middle-aged Women With Overweight/Obesity) NCT07480109
Aún no recluta
RESCUE: Interrupción de GLP-1 NCT07190794
Reclutando
Assess Impact of Microdroplet Hyaluronic Acid Filler on Skin Quality in Patients on Glucagon-like Peptide-1 Agonists NCT07221461
Aún no recluta
Protective Benefits of a Clear Liquid Diet on Residual Gastric Content in Patients Taking Glucagon Like Peptide-1 Receptor (GLP-1 RA) Agonist Prior to Anesthesia NCT06654219
Reclutando
Effect of Prolonged Fasting Time on Gastric Residual Volume in Patients Taking GLP1 Receptor Agonists NCT07006142
Reclutando
Beta-cell Response to Incretin Hormones in Cystic Fibrosis NCT01851694
Reclutando
Ellacor® Micro-Coring Technology® in Fitzpatrick Skin Types I-VI, Including Patients Receiving Glucagon-Like Peptide-1 Receptor Agonists NCT07224880
Reclutando
The Impact of GLP Medication on Colonoscopy Bowel Preparation Quality NCT07127354
Reclutando
PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes (PRECIDENTD) NCT05390892
Reclutando
The Role of Islet GLP-1 in the Pathogenesis of Prediabetes NCT06967558
Reclutando
Investigating the Impact of GLP-1 RA Therapy on Osteosarcopenia in Older Female Adults With Diabetes (GLOW) NCT07428746
Aún no recluta
Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass Surgery NCT00992901
Reclutando
Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study (CER-4-T2D) NCT05220917
Activo, no reclutando
Study of Once-Daily Oral RGT001-075 Compared With Placebo in Adults With Obesity or Are Overweight With Weight-Related Health Conditions (COMO-1) NCT06867718
Activo, no reclutando
The Effect of rs7903146 Genotype on Islet GLP-1 Production in Humans NCT06972407
Aún no recluta
Restoring Facial Volume After GLP-1 Weight Loss With Radiesse NCT07419854
Reclutando
Stanford Pediatric Healthy Weight Index NCT07316816
Reclutando
Effect of Supplement on Appetite and GLP-1 (GLP-1 Suppleme) NCT06790771
Aún no recluta
MAINTAIN (Mucosal AblatIoN Therapy After INcretins) NCT06734312
Reclutando
Digital Behavioral Therapy to Reduce Diabetes and Liver Disease Risk (SIPPA-QH_HHC-2) NCT07032311
Aún no recluta
Comparison of Body Composition Changes With Weight Loss Interventions (REFORM) NCT07115069
Reclutando
Strength Training Response of Muscle in GLP-1 Users (STRONG-GLP) NCT07104539
Reclutando
A Study of a Weight Loss Intervention in People With Endometrial Cancer NCT06751589
Reclutando
Effects of Glucagon-like Peptide-1 (GLP-1) Agonist in Neuro-reproductive Function in Obese Adolescent Females With Polycystic Ovary Syndrome (PCOS) NCT07169136
Reclutando
A Study to Evaluate the Efficacy and Safety of Once-Weekly MET097 in Adults With Obesity or Overweight and T2DM (VESPER-2) NCT06897202
Activo, no reclutando
GLP-1R Actions on Muscle and the Skeleton (GRAMS) NCT07154719
Aún no recluta
Lifestyle Change Implementation Research Network at PRC at UMass Chan (LCIRN) NCT07481305
Aún no recluta
Un estudio de fase 2b de 16 semanas para examinar la seguridad y eficacia de cuatro regímenes diferentes de MET-097 una vez a la semana (VESPER-1) NCT06712836
Activo, no reclutando
Efficacy and Safety of GZR18 Every 2 Weeks Versus Tirzepatide and Placebo in Obese or Overweight Participants NCT06737042
Aún no recluta
A Phase 2 Study Evaluating the Co-Administration of Bremelanotide With Tirzepatide for the Treatment of Obesity (BMT-801) NCT06565611
Activo, no reclutando
Weight Loss Management in Endometrial Cancer Survivors (ECS Weight) NCT06877572
Reclutando
Terapia con agonistas del receptor del péptido 1 similar al glucagón (GLP-1) y entrenamiento físico en personas con obesidad NCT07091500
Reclutando
Residual Gastric Content and GLP-1 NCT06814080
Reclutando
The Effect of Glycemic Control and of GLP-1 Receptor Agonism on Islet GLP-1 in People With Type 1 and Type 2 Diabetes NCT06976619
Reclutando
Pharmacogenetics of the Response to GLP-1 in Mexican-Americans With Prediabetes NCT05119179
Reclutando
A Study to Evaluate a Postbiotic in Supporting Weight Loss and Metabolic Health NCT06911073
Reclutando